Structured Review

Abbott Laboratories hcv rna
Distribution of <t>HCV-RNA</t> (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Hcv Rna, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcv rna/product/Abbott Laboratories
Average 94 stars, based on 45 article reviews
Price from $9.99 to $1999.99
hcv rna - by Bioz Stars, 2020-05
94/100 stars

Images

1) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

2) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

3) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

4) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

5) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

6) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

7) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

8) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

9) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

10) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

11) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

12) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

13) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

14) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

15) Product Images from "Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents"

Article Title: Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

Journal: PLoS Pathogens

doi: 10.1371/journal.ppat.1004128

Mutational analysis of viral variants with treatment of protease inhibitors or/and HTEIs in the long-term HCV infection assay. Clonal sequencing of HCV NS3 mutations in simeprevir monotherapy and the combination of simeprevir and anti-CLDN1 mAb. To further identify simeprevir induced DAA-resistance mutations, HCV RNA from (A) mock (CTRL), (B) 10 µg/mL anti-CLDN1 mAb, (C) 500 nM simeprevir or (D) 500 nM simeprevir +10 µg/mL anti-CLDN1 mAb treatment on day 23 as shown in Figure 5A and 6 was isolated and amplified as described in Materials and Methods. Following cloning and sequencing of the NS3 protease region, the relative distribution of viral variants (wild-type (WT) and NS3 mutations listed in a clockwise order beside the pie charts) was analyzed and is indicated in different shades of grey in the pie charts. The major DAA-resistance mutation, D168V, is highlighted in blue and WT is in light grey. For each variant, the number of detected clones is indicated in the parenthesis.
Figure Legend Snippet: Mutational analysis of viral variants with treatment of protease inhibitors or/and HTEIs in the long-term HCV infection assay. Clonal sequencing of HCV NS3 mutations in simeprevir monotherapy and the combination of simeprevir and anti-CLDN1 mAb. To further identify simeprevir induced DAA-resistance mutations, HCV RNA from (A) mock (CTRL), (B) 10 µg/mL anti-CLDN1 mAb, (C) 500 nM simeprevir or (D) 500 nM simeprevir +10 µg/mL anti-CLDN1 mAb treatment on day 23 as shown in Figure 5A and 6 was isolated and amplified as described in Materials and Methods. Following cloning and sequencing of the NS3 protease region, the relative distribution of viral variants (wild-type (WT) and NS3 mutations listed in a clockwise order beside the pie charts) was analyzed and is indicated in different shades of grey in the pie charts. The major DAA-resistance mutation, D168V, is highlighted in blue and WT is in light grey. For each variant, the number of detected clones is indicated in the parenthesis.

Techniques Used: Infection, Sequencing, Isolation, Amplification, Clone Assay, Mutagenesis, Variant Assay

HTEIs effectively block cell-cell transmission of DAA-resistant viruses. The experimental setup is shown in Figure 1C . NS5A + HCV producer cells (Pi) were transfected with HCV RNA encoding for HCV Jc1 NS3-A156S (A-B) or Jc1 NS3-L36M/R155K (C–D). NS5A+ HCV producer cells and GFP-expressing target cells (T) were co-cultivated with nAb (anti-HCV IgG, 25 µg/mL) to block cell-free transmission as described [6] . Cell-cell transmission of wild-type or drug-resistant strains was determined by quantification of GFP + NS5A + target cells (Ti) by flow cytometry. Protease or NS5A inhibitor-resistant HCV variant producer cells (Pi) cultured with uninfected target cells (T) were then incubated with 1 µg/mL of CLDN1-specific mAb or 10 µM of erlotinib or control medium. HCV-infected target cells (GFP + NS5A + ) were quantified by flow cytometry (A and C). Percentage of infected target cells is shown as histograms (B and D) and is represented as means ± SD from three experiments performed in triplicate. * p
Figure Legend Snippet: HTEIs effectively block cell-cell transmission of DAA-resistant viruses. The experimental setup is shown in Figure 1C . NS5A + HCV producer cells (Pi) were transfected with HCV RNA encoding for HCV Jc1 NS3-A156S (A-B) or Jc1 NS3-L36M/R155K (C–D). NS5A+ HCV producer cells and GFP-expressing target cells (T) were co-cultivated with nAb (anti-HCV IgG, 25 µg/mL) to block cell-free transmission as described [6] . Cell-cell transmission of wild-type or drug-resistant strains was determined by quantification of GFP + NS5A + target cells (Ti) by flow cytometry. Protease or NS5A inhibitor-resistant HCV variant producer cells (Pi) cultured with uninfected target cells (T) were then incubated with 1 µg/mL of CLDN1-specific mAb or 10 µM of erlotinib or control medium. HCV-infected target cells (GFP + NS5A + ) were quantified by flow cytometry (A and C). Percentage of infected target cells is shown as histograms (B and D) and is represented as means ± SD from three experiments performed in triplicate. * p

Techniques Used: Blocking Assay, Transmission Assay, Transfection, Expressing, Flow Cytometry, Cytometry, Variant Assay, Cell Culture, Incubation, Infection

Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA encoding wild-type HCV Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 µg/mL), simeprevir (500 nM) alone or in combination with anti-CLDN1 mAb (10 µg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification (LOQ), indicated by a dashed line, was 10 3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA detection assay, the Abbott RealTime HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 µL liquid sample). (B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means ± SD from a representative experiment performed in triplicate are shown.
Figure Legend Snippet: Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA encoding wild-type HCV Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 µg/mL), simeprevir (500 nM) alone or in combination with anti-CLDN1 mAb (10 µg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification (LOQ), indicated by a dashed line, was 10 3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA detection assay, the Abbott RealTime HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 µL liquid sample). (B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means ± SD from a representative experiment performed in triplicate are shown.

Techniques Used: Transfection, Reverse Transcription Polymerase Chain Reaction, RNA Detection, Quantitative RT-PCR, Infection

Analysis of DAA-resistant mutations emerged during treatment protocols by direct sequencing. In the long-term HCV infection assay shown in Figure 5A , HCV RNA in the supernatants from different treatments was purified on day 23. Direct sequencing was performed to identify predominant viral mutations in HCV NS3 protease region as described in Materials and Methods . Data are displayed as NS3 amino acid sequence in treated cells.
Figure Legend Snippet: Analysis of DAA-resistant mutations emerged during treatment protocols by direct sequencing. In the long-term HCV infection assay shown in Figure 5A , HCV RNA in the supernatants from different treatments was purified on day 23. Direct sequencing was performed to identify predominant viral mutations in HCV NS3 protease region as described in Materials and Methods . Data are displayed as NS3 amino acid sequence in treated cells.

Techniques Used: Sequencing, Infection, Purification

16) Product Images from "Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna"

Article Title: Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna

Journal: Wiener Klinische Wochenschrift

doi: 10.1007/s00508-016-1162-y

Treatment response. a Viral kinetics of HCV-RNA at baseline and during therapy (weeks 2 to 12) are shown as mean ± standard error of the mean at the respective time points for SOF/LDV and 2D/3D, respectively. b Proportion of patients with end of treatment negativity and SVR after cessation of therapy are shown for SOF/LDV and 2D/3D, respectively. c Changes in liver stiffness from baseline to follow-up (evaluated at SVR) are depicted for SOF/LDV and for 2D/3D patients, respectively. SOF sofosbuvir, LDV ledipasvir, 2D ritonavir boosted ombitasvir/paritaprevir, 3D ritonavir boosted ombitasvir/paritaprevir/dasabuvir, BL baseline, W treatment week, EOT end of treatment, SVR sustained virologic response, TND target not detectable
Figure Legend Snippet: Treatment response. a Viral kinetics of HCV-RNA at baseline and during therapy (weeks 2 to 12) are shown as mean ± standard error of the mean at the respective time points for SOF/LDV and 2D/3D, respectively. b Proportion of patients with end of treatment negativity and SVR after cessation of therapy are shown for SOF/LDV and 2D/3D, respectively. c Changes in liver stiffness from baseline to follow-up (evaluated at SVR) are depicted for SOF/LDV and for 2D/3D patients, respectively. SOF sofosbuvir, LDV ledipasvir, 2D ritonavir boosted ombitasvir/paritaprevir, 3D ritonavir boosted ombitasvir/paritaprevir/dasabuvir, BL baseline, W treatment week, EOT end of treatment, SVR sustained virologic response, TND target not detectable

Techniques Used:

HIV suppression during anti-HCV therapy. Proportion of patients with continuous complete suppression of HIV-RNA during anti-HCV treatment, or with detectable but not quantifiable HIV-RNA levels
Figure Legend Snippet: HIV suppression during anti-HCV therapy. Proportion of patients with continuous complete suppression of HIV-RNA during anti-HCV treatment, or with detectable but not quantifiable HIV-RNA levels

Techniques Used:

17) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

18) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

19) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

20) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

21) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

22) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

23) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

24) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

25) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

26) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

27) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

28) Product Images from "Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0"

Article Title: Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02102-13

Alignment of HCV 5′-untranslated sequences for two patients with HCV genotype 2a, in whom HCV RNA was undetectable by the CAP/CTM HCV v1.0 assay, against the sequence of a reference HCV genotype 2a strain (JFH-1). Nucleotide substitutions were
Figure Legend Snippet: Alignment of HCV 5′-untranslated sequences for two patients with HCV genotype 2a, in whom HCV RNA was undetectable by the CAP/CTM HCV v1.0 assay, against the sequence of a reference HCV genotype 2a strain (JFH-1). Nucleotide substitutions were

Techniques Used: Sequencing

29) Product Images from "Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro"

Article Title: Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro

Journal: Journal of Virology

doi: 10.1128/JVI.01790-17

Inhibition of HCV replication in CD4 + and CD8 + T lymphocytes by treatment with the HCV-specific protease inhibitor TLPV. Affinity-purified CD4 + and CD8 + T cells from donor A/M were exposed to authentic HCV-11/M or HCV-16/F in the presence of 4 μM TLPV (T, treated) or 0.5% DMSO alone (UT, TLPV untreated) for 72 h. Experiments with CD4 + and CD8 + T cells exposed to HCV-16/F and TLPV or 0.5% DMSO were done in duplicate, whereas those with HCV-11/M and TLPV or 0.5% DMSO were done once because to sparsity of the inoculum. The HCV RNA negative strand in CD4 + T cells (A) and CD8 + T cells (B) was identified by strand-specific RT-PCR/NAH in which sHCV RNA positive (pos) and negative (neg) strands at 1 × 10 4 copies/reaction were used as specificity controls. Water amplified in direct (DW) and nested (NW) reactions and a mock (M) extraction served as contamination controls. Positive signals demonstrated the expected 244-bp oligonucleotide fragments.
Figure Legend Snippet: Inhibition of HCV replication in CD4 + and CD8 + T lymphocytes by treatment with the HCV-specific protease inhibitor TLPV. Affinity-purified CD4 + and CD8 + T cells from donor A/M were exposed to authentic HCV-11/M or HCV-16/F in the presence of 4 μM TLPV (T, treated) or 0.5% DMSO alone (UT, TLPV untreated) for 72 h. Experiments with CD4 + and CD8 + T cells exposed to HCV-16/F and TLPV or 0.5% DMSO were done in duplicate, whereas those with HCV-11/M and TLPV or 0.5% DMSO were done once because to sparsity of the inoculum. The HCV RNA negative strand in CD4 + T cells (A) and CD8 + T cells (B) was identified by strand-specific RT-PCR/NAH in which sHCV RNA positive (pos) and negative (neg) strands at 1 × 10 4 copies/reaction were used as specificity controls. Water amplified in direct (DW) and nested (NW) reactions and a mock (M) extraction served as contamination controls. Positive signals demonstrated the expected 244-bp oligonucleotide fragments.

Techniques Used: Inhibition, Protease Inhibitor, Affinity Purification, Reverse Transcription Polymerase Chain Reaction, Amplification

Detection of HCV RNA positive and negative strands in CD4 + and CD8 + T lymphocytes infected with authentic HCV. Affinity-purified CD4 + and CD8 + T cells from healthy donors B/F and A/M pretreated with PHA were exposed to HCV-11/M or HCV-16/F plasma or to healthy donor plasma (HDP). (A) Cells from experiment 1 infected with HCV-11/M or exposed to HDP. (B) Cells from experiment 3 infected with HCV-11/M. (C) Cells from experiment 5 infected with HCV-11/M or exposed to HDP. (D) Cells from experiment 6 infected with HCV-16/F. CD4 + and CD8 + T cells were cultured under intermittent stimulation with PHA as described in Materials and Methods. When the numbers of cells recovered allowed, CD4 + and CD8 + T cells were also exposed to HDP and cultured under the same conditions as those for infected cells (mock infection). RNA was analyzed for HCV RNA positive and negative (replicative) strands by RT-PCR/NAH assays. Contamination and specificity controls included water added instead of cDNA and amplified by direct PCR (D/W) and, if applicable, nested PCR (N/W) and an RNA/cDNA-free mock (Mock) sample. The synthetic HCV RNA positive (HCV sRNA pos) strand at 1 × 10 6 copies was used as the positive and specificity control, and the rHCV UTR-E2 fragment at 1 × 10 6 copies was used as an additional positive control for the detection of the HCV RNA positive strand. Serial dilutions of the synthetic HCV RNA negative (HCV sRNA neg) strand and the HCV sRNA positive strand were used to confirm the specificity of detection and as quantitative standards for the detection of the HCV RNA negative strand. Positive signals showed the expected 442-bp (direct RT-PCR/NAH) or 244-bp (nested RT-PCR/NAH) oligonucleotide fragments.
Figure Legend Snippet: Detection of HCV RNA positive and negative strands in CD4 + and CD8 + T lymphocytes infected with authentic HCV. Affinity-purified CD4 + and CD8 + T cells from healthy donors B/F and A/M pretreated with PHA were exposed to HCV-11/M or HCV-16/F plasma or to healthy donor plasma (HDP). (A) Cells from experiment 1 infected with HCV-11/M or exposed to HDP. (B) Cells from experiment 3 infected with HCV-11/M. (C) Cells from experiment 5 infected with HCV-11/M or exposed to HDP. (D) Cells from experiment 6 infected with HCV-16/F. CD4 + and CD8 + T cells were cultured under intermittent stimulation with PHA as described in Materials and Methods. When the numbers of cells recovered allowed, CD4 + and CD8 + T cells were also exposed to HDP and cultured under the same conditions as those for infected cells (mock infection). RNA was analyzed for HCV RNA positive and negative (replicative) strands by RT-PCR/NAH assays. Contamination and specificity controls included water added instead of cDNA and amplified by direct PCR (D/W) and, if applicable, nested PCR (N/W) and an RNA/cDNA-free mock (Mock) sample. The synthetic HCV RNA positive (HCV sRNA pos) strand at 1 × 10 6 copies was used as the positive and specificity control, and the rHCV UTR-E2 fragment at 1 × 10 6 copies was used as an additional positive control for the detection of the HCV RNA positive strand. Serial dilutions of the synthetic HCV RNA negative (HCV sRNA neg) strand and the HCV sRNA positive strand were used to confirm the specificity of detection and as quantitative standards for the detection of the HCV RNA negative strand. Positive signals showed the expected 442-bp (direct RT-PCR/NAH) or 244-bp (nested RT-PCR/NAH) oligonucleotide fragments.

Techniques Used: Infection, Affinity Purification, Cell Culture, Reverse Transcription Polymerase Chain Reaction, Amplification, Polymerase Chain Reaction, Nested PCR, Positive Control

Detection of HCV RNA positive and negative strands in total T cells after in vitro infection by HCV-positive plasma from patients 11/M and 16/F. Monocyte-depleted PBMC from healthy donor A/M were pretreated with PHA, exposed to test inocula, and cultured as indicated in Materials and Methods. RNA from the cells collected at different days (d) postinfection was analyzed by RT-PCR/NAH for the expression of the HCV RNA positive strand (A) and the HCV RNA negative strand (B). Synthetic HCV RNA (HCV sRNA) positive (pos) and negative (neg) strands at 1 × 10 5 copies/reaction were used to confirm the specificity of detection. The rHCV UTR-E2 fragment at 1 × 10 5 copies/reaction served as an additional positive control for the detection of the HCV RNA positive strand. Water instead of cDNA amplified in direct (D/W) and nested (N/W) reactions as well as a mock-treated sample without RNA (Mock) were included as negative and contamination controls. Positive signals showed the expected 244-bp bands.
Figure Legend Snippet: Detection of HCV RNA positive and negative strands in total T cells after in vitro infection by HCV-positive plasma from patients 11/M and 16/F. Monocyte-depleted PBMC from healthy donor A/M were pretreated with PHA, exposed to test inocula, and cultured as indicated in Materials and Methods. RNA from the cells collected at different days (d) postinfection was analyzed by RT-PCR/NAH for the expression of the HCV RNA positive strand (A) and the HCV RNA negative strand (B). Synthetic HCV RNA (HCV sRNA) positive (pos) and negative (neg) strands at 1 × 10 5 copies/reaction were used to confirm the specificity of detection. The rHCV UTR-E2 fragment at 1 × 10 5 copies/reaction served as an additional positive control for the detection of the HCV RNA positive strand. Water instead of cDNA amplified in direct (D/W) and nested (N/W) reactions as well as a mock-treated sample without RNA (Mock) were included as negative and contamination controls. Positive signals showed the expected 244-bp bands.

Techniques Used: In Vitro, Infection, Cell Culture, Reverse Transcription Polymerase Chain Reaction, Expressing, Positive Control, Amplification

30) Product Images from "Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?"

Article Title: Serum Adiponectin, Vitamin D, and Alpha-Fetoprotein in Children with Chronic Hepatitis C: Can They Predict Treatment Response?

Journal: International Journal of Hepatology

doi: 10.1155/2015/617623

Diagnostic performance of pretreatment parameters for differentiation between responders and nonresponders. Receiver-operating characteristic (ROC) curves of (a) adiponectin, (b) vitamin D, (c) AFP, and (d) HCV-RNA level for differentiation between responders and nonresponders. The arrows indicate the cutoff values. AUROC: area under ROC.
Figure Legend Snippet: Diagnostic performance of pretreatment parameters for differentiation between responders and nonresponders. Receiver-operating characteristic (ROC) curves of (a) adiponectin, (b) vitamin D, (c) AFP, and (d) HCV-RNA level for differentiation between responders and nonresponders. The arrows indicate the cutoff values. AUROC: area under ROC.

Techniques Used: Diagnostic Assay

31) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

32) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

33) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

34) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

35) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

36) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

37) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

38) Product Images from "The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA"

Article Title: The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02004-12

Deming correlation and Bland-Altman plot analyses of HCV RNA levels determined by bDNA, CAP/CTM HCV, and CAP/CTM HCV v2.0 in 122 clinical samples (group A) containing different subtypes of HCV genotype 4. (A) Deming regression of CAP/CTM HCV versus bDNA. (B) Bland-Altman plots of CAP/CTM HCV versus bDNA. (C) Deming regression of CAP/CTM HCV v.2.0 versus bDNA. (D) Bland-Altman plots of CAP/CTM HCV v2.0 versus bDNA. (E) Deming regression of CAP/CTM HCV v2.0 versus CAP/CTM HCV. (F) Bland-Altman plots of CAP/CTM HCV v2.0 versus CAP/CTM HCV. In the Deming regression figures, the dashed line is the identity line; the black line surrounded by two dashed lines shows the Deming fit and 95% confidence interval, respectively. In the Bland-Altman figures, the difference between the HCV RNA levels obtained by the two assays is plotted as a function of the mean of the two values; the gray area and numbers correspond to the mean difference ± 1.96 standard deviation.
Figure Legend Snippet: Deming correlation and Bland-Altman plot analyses of HCV RNA levels determined by bDNA, CAP/CTM HCV, and CAP/CTM HCV v2.0 in 122 clinical samples (group A) containing different subtypes of HCV genotype 4. (A) Deming regression of CAP/CTM HCV versus bDNA. (B) Bland-Altman plots of CAP/CTM HCV versus bDNA. (C) Deming regression of CAP/CTM HCV v.2.0 versus bDNA. (D) Bland-Altman plots of CAP/CTM HCV v2.0 versus bDNA. (E) Deming regression of CAP/CTM HCV v2.0 versus CAP/CTM HCV. (F) Bland-Altman plots of CAP/CTM HCV v2.0 versus CAP/CTM HCV. In the Deming regression figures, the dashed line is the identity line; the black line surrounded by two dashed lines shows the Deming fit and 95% confidence interval, respectively. In the Bland-Altman figures, the difference between the HCV RNA levels obtained by the two assays is plotted as a function of the mean of the two values; the gray area and numbers correspond to the mean difference ± 1.96 standard deviation.

Techniques Used: Standard Deviation

39) Product Images from "Necessity for Reassessment of Patients with Serogroup 2 Hepatitis C Virus (HCV) and Undetectable Serum HCV RNA"

Article Title: Necessity for Reassessment of Patients with Serogroup 2 Hepatitis C Virus (HCV) and Undetectable Serum HCV RNA

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02792-13

Clinical course and histology of patient 1. (A) Changes in serum HCV RNA and alanine aminotransferase. (B) Liver histology indicating liver cirrhosis (AZAN staining, 4-fold original magnification). (C) Immunohistochemical staining with a monoclonal antibody
Figure Legend Snippet: Clinical course and histology of patient 1. (A) Changes in serum HCV RNA and alanine aminotransferase. (B) Liver histology indicating liver cirrhosis (AZAN staining, 4-fold original magnification). (C) Immunohistochemical staining with a monoclonal antibody

Techniques Used: Staining, Immunohistochemistry

Our first patient in whom serum HCV RNA was undetectable with CAP/CTM version 1 despite a high viral load with ART.
Figure Legend Snippet: Our first patient in whom serum HCV RNA was undetectable with CAP/CTM version 1 despite a high viral load with ART.

Techniques Used:

40) Product Images from "HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes"

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Journal: BMC Infectious Diseases

doi: 10.1186/1471-2334-14-222

Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
Figure Legend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

Techniques Used:

Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
Figure Legend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

Techniques Used:

Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.
Figure Legend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

Techniques Used: Infection

Related Articles

Amplification:

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: .. This has been confirmed in subsequent studies based on different HCV RNA quantification systems [ - , ]; in particular, very recently Descamps et al. [ ] found a very significant correlation of HCVAg to HCV-RNA, measured by TaqMan amplification (r = 0.90; p < 0.001) and an equivalency of 1 pg of HCVAg = 9,755 IU of HCV-RNA, that equals about 600 IU/mL at the HCVAg assay threshold of 3 fmol/L. .. From those data, confirmed also by our observation, only a portion of the circulating HCVAg seems to be associated with complete virions, implying that a variable fraction of circulating HCVAg may be secreted by the infected cells.

other:

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: The positivity rates for HCVAg according to different levels of HCV-RNA and the median levels are reported in Table .

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: The assay sensitivity across the different HCV genotypes ranges from 500 to 3,000 IU/mL of HCV-RNA [ - ].

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: The distribution of HCV-RNA and HCVAg levels according to HCV genotypes 1, 3 and 4 are reported in Figure .

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: For the measurement of HCV-RNA, a number of qualitative and quantitative assays are commercially available offering a very low limit of detection and linear quantification over a broad dynamic range [ - ].

Infection:

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: .. These results suggest that HCVAg represents an adequate tool for determining an ongoing HCV infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA. ..

Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Article Snippet: .. The current standard for diagnosing an active HCV infection is the detection and quantification of HCV-RNA, also recommended to monitor the antiviral treatment. .. Therapy guidelines for standard treatment with pegylated interferon (PEG-IFN) plus Ribavirin recommend the discontinuation of the therapy if HCV-RNA decline is < 2 log at week 12 or when HCV RNA is still detectable at week 24 [ ].

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Abbott Laboratories hcv rna
    Distribution of <t>HCV-RNA</t> (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
    Hcv Rna, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna/product/Abbott Laboratories
    Average 94 stars, based on 45 article reviews
    Price from $9.99 to $1999.99
    hcv rna - by Bioz Stars, 2020-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

    Article Snippet: The current standard for diagnosing an active HCV infection is the detection and quantification of HCV-RNA, also recommended to monitor the antiviral treatment.

    Techniques:

    Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

    Article Snippet: The current standard for diagnosing an active HCV infection is the detection and quantification of HCV-RNA, also recommended to monitor the antiviral treatment.

    Techniques:

    Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

    Article Snippet: The current standard for diagnosing an active HCV infection is the detection and quantification of HCV-RNA, also recommended to monitor the antiviral treatment.

    Techniques: Infection